Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Wins Genentech, But Will Biotech Employees Remain?

Executive Summary

After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake

You may also be interested in...

EMA Looks At Avastin, As Novartis/Roche Appeal Italian Competition Fines

With EMA deliberating about Avastin, Novartis and Roche have confirmed that they will appeal the €180.5 million fine imposed on them by Italy’s competition authority for anti-competitive behavior.

Blinding Them With Science: Genentech Tries To Win Shareholders Over

Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked

Roche Blinks But Is $93 Enough For Genentech Shareholders?

The $6.50 per share increase in Roche’s offer also includes an extension of the tender deadline to March 20.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts